Neumora Therapeutics Inc (NMRA) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form 8-K - Current report

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a...

Form 8-K - Current report

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2...

Neumora Therapeutics to Participate in Upcoming Conferences in November

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company...

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company...

Neumora Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company...